Viking Therapeutics (NASDAQ:VKTX) is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Founded in 2012 and headquartered in San Diego, California, Viking is advancing a portfolio of small-molecule programs designed to address conditions that currently lack effective treatments. The company’s strategy centers on harnessing insights into hormone signaling pathways and metabolic regulation to create differentiated therapies with the potential for significant clinical benefit.
The lead program, VK2809, is an oral, liver-directed thyroid receptor beta agonist in late-stage clinical development for the treatment of dyslipidemia and nonalcoholic steatohepatitis (NASH). Viking’s pipeline also includes VK0214, a selective thyroid receptor beta agonist being evaluated for X‐linked adrenoleukodystrophy (X-ALD), and VK2735, a growth hormone receptor antagonist for the treatment of acromegaly. Each program leverages the company’s proprietary chemistry platform to optimize potency, selectivity and safety profiles for chronic use.
Viking’s leadership team brings extensive experience in drug discovery, clinical development and regulatory affairs. Noel R. Castellano serves as President and Chief Executive Officer, guiding the company’s strategic direction and clinical development efforts. Under his tenure, Viking has successfully completed multiple clinical milestones, including Phase 2 studies for VK2809, and has engaged in scientific collaborations to advance its research capabilities.
With operations primarily in the United States, Viking Therapeutics also maintains relationships with global research institutions and contract research organizations to support its international clinical trial activities. The company seeks to address a range of serious metabolic and endocrine diseases through innovation in hormone receptor biology, aiming to improve outcomes for patients worldwide.
